The simultaneous large buy and sell by two major 10% owners creates a split signal. EcoR1's $4.74M purchase is a bullish vote of confidence, but Panacea's $3.17M sale suggests some insiders are taking profits.
ATRA drugs
ATRA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $9.93entry
- T+1 · 6mo ago −16.01%α −16.84% · $8.34
- T+5 · 6mo ago +5.54%α +4.03% · $10.48
- T+20 · 6mo ago −3.02%α −6.16% · $9.63
- T+60 · 4mo ago −13.90%α −17.73% · $8.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director/10% owner Panacea Innovation sold $3.17M worth on the same day. The net $1.57M buying is modest relative to ATRA's $71M market cap (~2.2%), but the simultaneous insider buying and selling creates a conflicting signal that warrants caution.
Key Financial Metrics
Key Facts
- EcoR1 Capital purchased 507,407 shares at $9.35 for $4.74M on 2026-05-07
- Panacea Innovation sold 313,446 shares at $10.10 for $3.17M on 2026-05-07
- Net insider buying of ~$1.57M, representing ~2.2% of ATRA's $71M market cap
- Both parties are 10% owners; no C-suite insiders traded
Financial Impact
Net insider buying of ~$1.57M, ~2.2% of market cap
Risk Factors
- Insider selling by a 10% owner may signal lack of confidence in near-term prospects
- No C-suite participation reduces the signal strength of insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ATRA-1778539528445 |
Track record
11 reports on ATRA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
- Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- May 7, 202627w ago Insider Cluster Mixed 5/10 Viewing Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
- Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
- Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
- Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers